Simeprevir (CAS 923604-59-5)

Simeprevir is a macrocyclic compound that functions as a potent inhibitor of the hepatitis C virus (HCV) protease enzyme, specifically targeting the NS3/4A serine protease. This enzyme is crucial for the proteolytic cleavage of the HCV polyprotein into smaller, functional proteins necessary for viral replication. By inhibiting this protease, simeprevir disrupts the viral lifecycle, preventing the maturation of viral particles. In scientific research, simeprevir is used to study the dynamics of HCV replication and the mechanisms through which the virus evades the host immune response. The molecule′s strong binding affinity for the NS3/4A protease makes it an excellent tool for dissecting the enzyme′s role in the viral replication cycle. Researchers use simeprevir to understand how modifications in the protease′s structure affect its interaction with inhibitors and to map the enzyme′s active site in detail. Additionally, simeprevir serves as a model compound in the development of new antiviral agents. Its macrocyclic structure provides insights into how ring-size and functional groups contribute to efficacy and specificity. Researchers explore these aspects to design more potent inhibitors against various viral proteases by studying simeprevir′s structure-activity relationships. Simeprevir is also used in studies focused on viral resistance. By applying the compound in long-term cultures of HCV, scientists can induce mutations in the viral protease and study the emergence of resistance. These studies help in understanding the genetic mechanisms that underlie resistance and guide the development of inhibitors that can overcome these barriers.